Leuven - ThromboGenics NV today announced that the protocol of the Phase II CIRCLE Trial Evaluating Multiple Doses of THR-409 to induce a Total Posterior Vitreous Detachment in Patients with Non-Proliferative Diabetic Retinopathy (NPDR) has been amended.

The changes will allow inclusion of patients with less severe non-proliferative diabetic retinopathy (ETDRS level 43A - 47A). This will result in a broader patient pool for the study to recruit from.

The amended study, which focuses on assessing the ability of multiple doses of THR-409 to induce a total PVD in patients with NPDR, is now expected to enroll approximately 115 patients.

ThromboGenics NV published this content on 23 December 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 23 December 2016 06:33:07 UTC.

Original documenthttp://thrombogenics.com/content/thrombogenics-announces-protocol-amendment-phase-ii-circle-trial-evaluating-thr-409

Public permalinkhttp://www.publicnow.com/view/E814612461FFBCC40DDBB514A4AE0BC559C3674D